The DOI matches its Crossref record; 179 of the 181 references it cites were found in a registry or an index, and 2 are not checked yet.
Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes
Open accessAbstract
Cannabis extracts and synthetic cannabinoids are still widely considered illegal substances. Preclinical and clinical studies have suggested that they may result useful to treat diverse diseases, including those related with acute or chronic pain. The discovery of cannabinoid receptors, their endogenous ligands, and the machinery for the synthesis, transport, and degradation of these retrograde messengers, has equipped us with neurochemical tools for novel drug design. Agonist-activated cannabinoid receptors, modulate nociceptive thresholds, inhibit release of pro-inflammatory molecules, and display synergistic effects with other systems that influence analgesia, especially the endogenous opioid system. Cannabinoid receptor agonists have shown therapeutic value against inflammatory and neuropathic pains, conditions that are often refractory to therapy. Although the psychoactive effects of these substances have limited clinical progress to study cannabinoid actions in pain mechanisms, preclinical research is progressing rapidly. For example, CB(1)mediated suppression of mast cell activation responses, CB(2)-mediated indirect stimulation of opioid receptors located in primary afferent pathways, and the discovery of inhibitors for either the transporters or the enzymes degrading endocannabinoids, are recent findings that suggest new therapeutic approaches to avoid central nervous system side effects. In this review, we will examine promising indications of cannabinoid receptor agonists to alleviate acute and chronic pain episodes. Recently, Cannabis sativa extracts, containing known doses of tetrahydrocannabinol and cannabidiol, have granted approval in Canada for the relief of neuropathic pain in multiple sclerosis. Further double-blind placebo-controlled clinical trials are needed to evaluate the potential therapeutic effectiveness of various cannabinoid agonists-based medications for controlling different types of pain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The capsaicin receptor: a heat-activated ion channel in the pain pathway
Caterina, M. J., Schumacher, M. A., Tominaga, M., Rosen, T. A., Levine, J. D., & Julius, D. (1997) · Nature · doi:10.1038/39807 · Cited by 9,107
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633 · cited 1×
“The first endocannabinoid isolated (from porcine brain) and structurally characterised was arachidonylethanolamide (AEA), commonly designated anandamide [30].”
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 2×
“Two have been cloned, type 1 (CB1) and type 2 (CB2) cannabinoid receptors [100, 108], while the other two, WIN and abnormal-cannabidiol (abn-CBD) receptors (the latter also known as anandamide receptor), have been characterised pharmacologically [8, 31, 51, 71, 107].”
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011 · cited 2×
“Two have been cloned, type 1 (CB1) and type 2 (CB2) cannabinoid receptors [100, 108], while the other two, WIN and abnormal-cannabidiol (abn-CBD) receptors (the latter also known as anandamide receptor), have been characterised pharmacologically [8, 31, 51, 71, 107].”
Ledent, C., Valverde, O., Cossu, G., Petitet, F., Aubert, J.-F., Beslot, F., Böhme, G. A., Imperato, A., Pedrazzini, T., Roques, B. P., et al. (1999) · Science · doi:10.1126/science.283.5400.401 · Cited by 3,614 · cited 2×
“A number of synthetic cannabinoid receptor agonists and antagonists have been formulated and genetically modified mice have been produced [13, 27, 86].”
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Determination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443 · cited 1×
“In the late 1980s, Howlett and colleagues [29] identified and characterised a receptor in rat brain that met criteria for a high-affinity, stereoselective, pharmacologically distinct cannabinoid receptor, by means of radiolabelled agonist ligand binding and functional assays for G-protein coupled…”
Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Gaoni, Y., & Mechoulam, R. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01062a046 · Cited by 2,393 · cited 1×
“In 1964, Mechoulam and colleagues [42] found that delta-9-tetrahydrocannabinol (THC) was the major psychoactive ingredient of cannabis.”
Herkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159 · cited 1×
“Their distribution has been mapped by autoradiographic studies, immunohistochemical techniques, in situ histochemistry, and electrophysiological studies [53, 78, 140].”
Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses
Wilson, R. I., & Nicoll, R. A. (2001) · Nature · doi:10.1038/35069076 · Cited by 1,607 · cited 1×
“However, if the CB1 receptor agonist remains present, the depolarisation phenomenon is blocked by occlusion [115, 175] and inhibitory inputs are transient.”
Research works printed but not linked: 1
- [47]Grinspoon L, Bakalar JB. Marihuana the forbidden medicine. New Haven: Yale University Press; 1997. [Google Scholar]
Cited by
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision
Attal, N., Cruccu, G., Baron, R., Haanpää, M., Hansson, P., Jensen, T. S., & Nurmikko, T. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.02999.x · Cited by 1,873
Pathological and protective roles of glia in chronic pain
Milligan, E. D., & Watkins, L. R. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2533 · Cited by 1,399
“For example, cannabinoid receptors, both type 1 (CB1) and type 2 (CB2), are being explored as therapeutic targets for inflammatory neurodegenerative diseases and neuropathic pai”
BackgroundThe effect of pain on cognitive function: A review of clinical and preclinical research
Moriarty, O., McGuire, B. E., & Finn, D. P. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.01.002 · Cited by 1,122
“Cannabinoid ligands have also demonstrated antinociceptive effects in acute, inflammatory and neuropathic pain models (Finn and Chapman, 2004; Manzanares et al., 2006), and have a synergistic analgesic effect when coadministered with opioids (Welch and Eads, 1999).”
Backgroundβ‐caryophyllene and β‐caryophyllene oxide—natural compounds of anticancer and analgesic properties
Fidyt, K., Fiedorowicz, A., Strządała, L., & Szumny, A. (2016) · Cancer Medicine · doi:10.1002/cam4.816 · Cited by 674
“In contrast, indirect analgesic responses are related to inhibition of the release of proinflammatory factors or/and may engage other systems involved in analgesia, such as endogenous opioid system [64].”
BackgroundCannabinoids and Cytochrome P450 Interactions
Zendulka, O., Dovrtělová, G., Nosková, K., Turjap, M., Šulcová, A., Hanuš, L., & Juřica, J. (2016) · Current Drug Metabolism · doi:10.2174/1389200217666151210142051 · Cited by 291
“N-arachidonoyldopamine (NADA) is another endocannabinoid known to exert significant biological activity, e.g. in the immune system and pain perception [59, 60].”
BackgroundMethodInfluential
Metadata
- Authors
- Manzanares, J., Julian, M., & Carrascosa, A.
- Affiliations
- Consejo Superior de Investigaciones Científicas (ES)
- Corresponding author
- Carrascosa, A.
- Venue
- Current Neuropharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2006-07-01
- Volume
- 4
- Issue
- 3
- Pages
- 239-257
- ISSN
- 1570-159X (ISSN-L)
- PMC
- PMC2430692
- OpenAlex
- W2166781208
- Cited by
- 287
- References
- 179
- Citations by year
- 2026: 13 · 2025: 21 · 2024: 19 · 2023: 27 · 2022: 23 · 2021: 30 · 2020: 28 · 2019: 16 · 2018: 16 · 2017: 24 · 2016: 13 · 2015: 13 · 2014: 11 · 2013: 6 · 2012: 9
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Current Neuropharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- endocannabinoid system, pain management, cannabinoid receptor agonists, acute pain, chronic pain, neuropathic pain, inflammatory pain, CB1 receptor, CB2 receptor, endocannabinoids, opioid system, mast cell activation, multiple sclerosis, tetrahydrocannabinol, cannabidiol, Cannabis sativa, analgesia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes. https://app.cochat.ai/papers/10.2174/157015906778019527
- The paper
- Manzanares, J., Julian, M., & Carrascosa, A. (2006). Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes. Current Neuropharmacology. https://doi.org/10.2174/157015906778019527
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.